tbuckley/cabot-search huggingface dataset:
P-419 Safety and effectiveness analysis of neoadjuvant chemoradiation plus consolidative chemotherapy with concurrent anti-PD-1 therapy in mid-low locally advanced rectal cancer
Authors: X. Liu, L. He, W. Tong, S. Li, M. Li, X. Sun, Y. Li, M. Gu, T. Xu, P. Chang, Q. Wang
Journal: Annals of Oncology (2023)
P-112 Assessing the accuracy of CT staging for tumor and nodal staging in colon cancer
Authors: J. Yu, S. Lee, O. Castillo, J. Sandhu, A. Ostowari, F. Dehkordi-Vakil, R. Kampalath, C. Chantaduly, P. Chang, S. Krishnamurthi, M. Senthil
Journal: Annals of Oncology (2023)
SO-31 Comprehensive genomic profiling of tumor tissue and plasma-circulating tumor DNA in RAS/BRAFV600E wild type metastatic colorectal cancer patients: Initial findings from the CAPRI 2-GOIM trial
Authors: G. Martini, E. Martinelli, D. Ciardiello, A. Nicastro, T. Latiano, E. Maiello, A. Avallone, E. Tamburini, S. Lonardi, C. Cremolini, I. Lolli, G. Tortora, A. Febbraro, S. Leo, M. Zampino, S. Napolitano, N. Normanno, T. Troiani, F. Ciardiello
Journal: Annals of Oncology (2023)
P-310 Prognostic impact of neutrophil-to-lymphocyte ratio and malnutrition in de novo metastatic pancreatic cancer
Authors: M. Freitas, C. Almeida, C. Teixeira, M. Goncalves, M. Couto, T. Lemos, I. Rego, M. Ribeiro, A. Coelho, S. Meireles, C. Sarmento, M. Barbosa
Journal: Annals of Oncology (2023)
P-370 The role of Ca 19-9 in progression, recurrence and survival of borderline resectable pancreatic cancer
Authors: C. Almeida, M. Goncalves, M. Freitas, C. Teixeira, M. Couto, T. Lemos, S. Meireles, I. Rego, C. Sarmento, A. Coelho, A. Costa, M. Barbosa
Journal: Annals of Oncology (2023)
P-377 Prognostic stratification of TAS-102 treatment
Authors: M. Goncalves, C. Teixeira, C. Almeida, M. Freitas, M. Couto, T. Lemos, I. Rego, C. Fernandes, C. Sarmento, N. Tavares, M. Barbosa, S. Meireles
Journal: Annals of Oncology (2023)
PD-2 Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies
Authors: J. Veas, M. Piñol, M. Sorolla, E. Parisi, A. Sorolla, M. Santacana, M. Ruiz, G. Parra, C. Aracil, A. Escartin, F. Vilardell, A. Salud, R. Montal
Journal: Annals of Oncology (2023)
P-350 An improved personalized medicine network: The PLATON from GI and beyond
Authors: A. Vogel, T. Goetze, A. Saborowski, N. Agaoglu, A. Reinacher-Schick, B. Westphalen, P. Wild, A. Stein, C. Pauligk, B. Zäpf, S. Al-Batran
Journal: Annals of Oncology (2023)
P-384 TP53 protein expression in colorectal cancer
Authors: I. Ben Ayed, S. Ben Nasr, A. Jaballah-Gabteni, H. Yaïche, N. Ben Jemii, D. Wider, T. Laasili, S. Boubaker, A. Haddauoi, H. Guettiti Tounsi-Kettiti
Journal: Annals of Oncology (2023)
P-252 Comparison of second-line treatment after GEM/nab-PTX therapy for metastatic pancreatic cancer
Authors: K. Takeshita, O. Akihiro, C. Morizane, D. Yamashige, K. Okamoto, H. Hara, Y. Hagiwara, D. Agarie, T. Takasaki, Y. Kawasaki, Y. Maruki, Y. Nagashio, S. Kondo, S. Hijioka, H. Ueno, T. Okusaka
Journal: Annals of Oncology (2023)
P-272 Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy
Authors: F. Keane, D. Cowzer, D. Khalil, J. Shia, R. Do, S. Folorunso, I. El Dika, A. Yaqubie, T. Kim, E. O'Reilly, G. Abou-Alfa, J. Harding
Journal: Annals of Oncology (2023)
P-138 Retrospective analysis of management of BRAF V600E mutated colorectal cancer in a single institution
Authors: R. Pérez Velasco, P. Macías Rodríguez, C. Garcia Grove, D. Martín Sánchez, C. Torrado, A. Barroso, F. Tallafigo, E. Monescillo, R. Buezas Pérez, J. Torres Sempere, A. Pereira Vicente, M. Valladares-Ayerbes, A. López Ladrón, J. Rodriguez, L. Limon, I. Gallego Jimenez
Journal: Annals of Oncology (2023)
SO-13 Outcomes and a prognostic classifier in 130 patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
Authors: G. Randon, Y. Aoki, R. Cohen, V. Nasca, S. Klempner, S. Maron, R. Cerantola, L. Fornaro, M. Ambrosini, P. Manca, M. Salati, A. Kawazoe, Z. Valerie, D. Cowzer, V. Genovesi, S. Lonardi, K. Shitara, T. André, F. Pietrantonio
Journal: Annals of Oncology (2023)
P-289 Prognostic role of clinical and pathobiological factors in patients with locally advanced gastric and esophagogastric junction cancers: Potential implications in the post-operative strategy
Authors: N. Liscia, L. Albarello, S. Camera, A. Casadei-Gardini, S. Foti, M. Ronzoni, D. Spanu, A. Damascelli, S. Massaron, E. Treppiedi, U. Elmore, F. Puccetti, A. Cossu, L. Barbieri, M. Scartozzi, S. Cascinu, R. Rosati, E. Mazza
Journal: Annals of Oncology (2023)
P-251 Prospective validation of the Asian Pacific Colorectal Screening (APCS) score to detect colorectal neoplasia among Mexican subjects undergoing screening colonoscopy
Authors: M. Meneses-Medina, F. Huitzil-Melendez, L. Uscanga-Dominguez, F. Valdovinos-Andraca, M. Cisneros-Cordero, C. Sandoval-Arce, L. Torres-Valdiviezo, J. Hernandez-Felix, M. Lajous-Loaeza, M. Jimenez-Meza, R. Valdez-Echeverria, V. Rosas-Camargo, A. Cedro-Tanda, L. Anaya-Sanchez
Journal: Annals of Oncology (2023)
P-249 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
Authors: L. Angotti, J. Lucchetti, A. Cortellini, M. Basso, M. Polito, F. Zoratto, E. Di Giacomo, M. Calegari, F. Lo Prinzi, D. Gemma, C. Signorelli, M. Veroli, G. Trombetta, S. Guerriero, L. Galbato Muscio, B. Di Cocco, F. Schietroma, A. Anghelone, B. Vincenzi, G. Tonini
Journal: Annals of Oncology (2023)
P-360 Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis
Authors: G. Trovato, G. Valente, M. Calegari, E. Dell’Aquila, A. Anghelone, J. Lucchetti, F. Schietroma, I. Zurlo, C. Signorelli, C. Morelli, F. Zoratto, G. Caira, A. Spring, R. Saltarelli, A. Cosimati, M. Schirripa, F. Santamaria, L. Angotti, L. Salvatore, C. Pozzo, M. Basso, G. Tortora
Journal: Annals of Oncology (2023)
P-291 Missing colorectal liver metastases after neoadjuvant chemotherapy: Can we improve the prognosis?
Authors: E. Fernandez de Sevilla, M. Collard, I. Sourrouille, L. Benhaim, C. Smolenschi, V. Boige, M. Ducreux, M. Gelli
Journal: Annals of Oncology (2023)
P-149 QUATTRO-II: A multicenter randomized trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Efficacy and safety analysis
Authors: M. Kotaka, H. Bando, H. Satake, D. Kotani, T. Hamaguchi, M. Shiozawa, T. Ikumoto, T. Masuishi, H. Yasui, Y. Kagawa, E. Oki, Y. Yamamoto, H. Kawakami, S. Boku, Y. Komatsu, H. Taniguchi, K. Muro, K. Yamazaki, T. Misumi, T. Yoshino, T. Kato, A. Tsuji
Journal: Annals of Oncology (2023)
P-281 Safety analysis and preliminary clinical results of REPROGRAM-01 phase II study evaluating regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
Authors: C. Borg, E. Klajer, A. El Kaddissi, F. Ghiringhelli, S. Kim, D. Vernerey, J. Henriques, T. Nguyen, A. Meurisse, S. Fratte, F. Fein, L. Spehner, M. Rebucci-Peixoto, A. Vienot
Journal: Annals of Oncology (2023)
P-286 Clinicopathological profile and outcomes in locally advanced rectal cancer with major pathological response following neoadjuvant therapy
Authors: A. Gammoudi, A. Gabsi, I. Belaid, Y. Zenzri, F. Letaief-Ksontini, K. Meddeb, H. Rais, F. Ezzairi, M. Ayadi, S. Ahmed, A. Mezlini
Journal: Annals of Oncology (2023)
P-230 Biomarkers associated with survival benefit to atezolizumab and bevacizumab for treatment of metastatic anal cancer
Authors: V. Morris, H. Zhu, X. Li, B. Johnson, S. Prasad, A. Mahvash, B. Sun, S. Gite, R. Panduregan, E. Parra, M. Knafl, S. Woodman, C. Eng, D. Halperin
Journal: Annals of Oncology (2023)
P-308 Novel gold (III) TGS121 complex selectively affects proteostasis of Ras-hyperactivated colorectal cancer cells via a shift in signaling pathways
Authors: S. Lipiec, I. Agnieszczak, J. Masztalerz, None Ů Szeleszczuk, J. Fichna, I. Młynarczuk-Biały
Journal: Annals of Oncology (2023)
P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study
Authors: C. Signorelli, M. Calegari, M. Basso, A. Anghelone, J. Lucchetti, A. Minelli, L. Angotti, I. Zurlo, M. Schirripa, M. Chilelli, C. Morelli, E. Dell’Aquila, A. Cosimati, D. Gemma, M. Ribelli, D. Corsi, G. Arrivi, F. Zoratto, M. Morandi, F. Santamaria, R. Saltarelli, E. Ruggeri
Journal: Annals of Oncology (2023)
P-342 Prospective, observational study evaluating the effectiveness and safety of aflibercept plus FOLFIRI in metastatic colorectal cancer (mCRC) according to Polish reimbursement criteria
Authors: A. Durbajlo, M. Swiezynski, A. Chrzanowska-Kapica, I. Drab-Mazur, M. Kulma-Kreft, M. Sikora-Skrabaka, E. Matuszewska, R. Wisniowski, K. Wierzbicka, L. Wyrwicz
Journal: Annals of Oncology (2023)
P-94 Overview of clinicopathological and prognostic factors for long-term survivors of pancreatic cancer from a multicenter study of 532 patients
Authors: I. Garajová, A. Comandatore, F. Gelsomino, S. De Lorenzo, V. Agnetti, A. Spallanzani, G. Martinelli, F. Leonardi, M. Palmeri, G. Di Franco, N. Furbetta, N. Ramacciotti, E. Giovannetti, L. Morelli
Journal: Annals of Oncology (2023)
P-404 Survival outcomes and prognostic factors in high risk locally advanced rectal cancers (LARC) undergoing concurrent capecitabine and long course radiation (Cape – RT) – results of a large cohort study
Authors: M. Reddy Yallala, A. Shah, V. Ostwal, A. Saklani, M. Kazi, R. Engineer, P. Bhargava, S. Srinivas, A. Ramaswamy, S. Ankathi, A. Baheti
Journal: Annals of Oncology (2023)
P-56 Brightline-2: A phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours
Authors: T. Macarulla, J. Harding, C. Morizane, K. Ohkawa, M. Ueno, A. Vogel, A. Lamarca, N. Yamamoto, M. Javle, J. Hu, M. Teufel, A. Märten, L. Goyal, C. Yoo
Journal: Annals of Oncology (2023)
P-301 Benefit of adding bevacizumab to trifluridine/tipiracil in different prognostic groups of metastatic colorectal cancer: A Portuguese exploratory analysis
Authors: R. Roque, A. Coelho, S. Brasil, R. Antunes Santos, L. Santos, I. Gomes, T. Fraga, A. Caetano, J. Paulo, N. Bonito
Journal: Annals of Oncology (2023)
O-2 Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
Authors: J. Knox, I. Bazin, D. Oh, O. Zubkov, V. Breder, L. Bai, A. Christie, M. McNamara, L. Goyal, D. Cosgrove, C. Springfeld, K. Sjoquist, J. Park, H. Verdaguer, C. Braconi, P. Ross, A. de Gramont, R. Shroff, J. Zalcberg, D. Palmer, J. Valle
Journal: Annals of Oncology (2023)
P-328 Dihydropyrimidine dehydrogenase deficiency frequency and its impact on 5-fluorouracil (5-FU) based chemotherapy toxicity
Authors: H. Lakhdari, A. Belhadj, N. Mkedder, S. Chaibdra Tani, S. Ghomari-Bezzar
Journal: Annals of Oncology (2023)
P-136 Increased healthcare costs due to diagnostic imaging services following false elevation of plasma chromogranin A and 24-hour urinary 5-hydroxyindoleacetic acid: A quality improvement project
Authors: B. Laderian, W. Wei, N. Farha, P. Mundi, P. Rao, E. Balagamwala, S. Steele, N. Vijayvergia, M. Sadaps, C. Chandrasekharan, A. Mohamed, K. Pacak
Journal: Annals of Oncology (2023)
P-361 Safety and efficacy of short cetuximab infusion for patients with metastatic colorectal cancer
Authors: K. Alshammari, R. Alanazi, M. Mohamed Ali, A. Abushara, A. Al-Abdulaali, F. Alotaibi, H. Shehata, M. Alkaiyat, J. Al Qahtani, A. Alolayan, M. Algarni
Journal: Annals of Oncology (2023)
P-240 Frequency and management of trifluridine/tipiracil (FTD/TPI) + bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practice
Authors: N. Martínez Lago, C. Reboredo Rendo, T. Calleja Chucla, M. Mateos Salvador, F. Busto Fernandez, J. de la Cámara Gómez, M. Reboredo-Lopez
Journal: Annals of Oncology (2023)
P-166 Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma
Authors: A. Pretta, G. Pinna, P. Ziranu, C. Donisi, G. Deias, E. Palmas, F. Loi, E. Cimbro, A. Cadoni, S. Murgia, S. Mariani, D. Rizzo, V. Dell'Utri, A. D'Agata, F. Bardanzellu, A. Maccioni, M. Puzzoni, V. Pusceddu, E. Lai, M. Scartozzi
Journal: Annals of Oncology (2023)
LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study
Authors: A. Kawazoe, R. Xu, M. Passhak, H. Teng, A. Shergill, M. Gumus, C. Qvortrup, S. Stintzing, K. Towns, T. Kim, K. Shiu, J. Cundom, S. Ananda, A. Lebedinets, R. Fu, R. Jain, D. Adelberg, V. Heinemann, T. Yoshino, E. Élez
Journal: Annals of Oncology (2023)
P-338 Second-line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first-line treatment with gemcitabine and nab-paclitaxel
Authors: T. McSweeney, A. Das, A. O'Mahony, F. O'Tighearnaigh, L. O'Byrne, M. Feely, E. Passmore, S. Keane, S. Lanigan, S. Fitzgerald, T. Browne, V. De Beer, A. Dean
Journal: Annals of Oncology (2023)
SO-9 The relationship between primary tumour-infiltrating immune cells and immune activation status of tumour draining lymph nodes in oesophageal cancer patients – results from the UK MRC OE02 trial
Authors: M. Kloft, W. Allum, D. Cunningham, R. Langley, M. Nankivell, D. Magee, H. Grabsch
Journal: Annals of Oncology (2023)
P-31 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Authors: E. Dumbrava, D. Olson, M. George, S. Saibil, G. Antonio, R. Bouvier, M. Gavriliuc, B. Pieke, E. Lichtenstein, J. Geisberger, M. Apostolopoulou, K. Moss, N. Ternus, D. Adib, B. Schlechter
Journal: Annals of Oncology (2023)
P-355 Recruitment of gastrointestinal cancer patients via PLATON Network: An interactive precision oncology platform
Authors: S. Al-Batran, T. Goetze, A. Saborowski, N. Agaoglu, C. Dreyling, S. Lorenzen, D. Modest, M. Schuler, B. Westphalen, P. Wild, B. Zäpf, A. Vogel
Journal: Annals of Oncology (2023)
PD-10 Organoids as tools for functional precision oncology in advanced pancreatic cancer
Authors: A. Boileve, N. Goudarzi, J. Cartry, S. Bedja, J. Mathieu, A. Mouawia, C. Nicotra, M. Ngo-Camus, K. Lipson, V. Boige, D. Malka, M. Valéry, A. Tarabay, M. Bani, P. Dartigues, T. De Baere, A. Italiano, M. Gelli, C. Smolenschi, M. Ducreux, A. Hollebecque, F. Jaulin
Journal: Annals of Oncology (2023)
SO-12 CLDN18.2 expression in resectable gastroesophageal cancers: Associated clinical and molecular signatures and impact of neoadjuvant chemotherapy on intratumor heterogeneity
Authors: A. Cammarota, G. Devonshire, A. Miremadi, L. Zhuang, S. Zamani, R. Smith, N. Masqué-Soler, A. Ustaoglu, L. Rimassa, R. Fitzgerald, E. Smyth
Journal: Annals of Oncology (2023)
P-182 Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer
Authors: R. Álvarez Gallego, R. Pazo Cid, B. López de San Vicente, T. Macarulla, E. Martinez de Castro, F. Garicano Goldaraz, M. Granja, I. Ghanem, J. Martinez-Galán, P. Ribera Fernández, R. Díaz Beveridge, J. Martín Valadés, C. Ángeles, A. Cubillo
Journal: Annals of Oncology (2023)
P-254 Outcomes and prognostic factors of resected pancreatic ductal adenocarcinoma in Saudi Arabia
Authors: K. Alshammari, A. Samman, F. Alotaibi, F. Almugbel, A. Aldeheshi, A. AlJuhani, M. Al-Hajeili, M. Alghamdi, A. Alfakeeh, A. Alzahrani, W. Alghareeb, A. Alnekhilan, N. Bukhari, A. Qudaih, M. Shaheen, H. Shehata, M. Alkaiyat, J. Al Qahtani, M. Algarni
Journal: Annals of Oncology (2023)
P-97 Enhanced recovery protocol (ERAS) in colorectal surgery and its effect on the survival of patients in the medium term (3 years)
Authors: A. Cuadrado-García, D. Serralta DeColsa, J. Gajda, M. Roca Doblado, I. Ortega, R. Fernandez, A. Picardo
Journal: Annals of Oncology (2023)
P-114 The therapeutic potential of nuclear receptor RORy in hepatocellular carcinoma
Authors: J. Cools-Lartigue, J. Tchervenkov, L. Ferri, B. Giannias, F. Bourdeau, S. Negi, S. Paraskevas, A. Brassard, I. Dhoparee-Doomah, L. Feng, X. Su, S. Leo, Q. Qiu, C. Sillcox, M. Shahzad
Journal: Annals of Oncology (2023)
Increased expression or activation of TRPML1 reduces hepatic storage of toxic Z alpha-1 antitrypsin
Authors: Nunzia Pastore, Francesco Annunziata, Rita Colonna, Veronica Maffia, Teresa Giuliano, Bruno Maria Custode, Bernadette Lombardi, Elena Polishchuk, Vincenzo Cacace, Lucia De Stefano, Edoardo Nusco, Nicolina Cristina Sorrentino, Pasquale Piccolo, Nicola Brunetti-Pierri
Journal: Molecular Therapy (2023)
P-125 Current practices in metastatic colorectal cancer: Results from the real-world screening and consensus based on practices and evidence (SCOPE) program in gastrointestinal cancers
Authors: G. Prager, D. Santini, D. Modest, F. Rivera, J. Phelip, M. Dioca, E. Smyth, A. Zaanan, S. Boeck, H. Wasan
Journal: Annals of Oncology (2023)
SO-26 Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
Authors: A. De Stefano, F. Giuliani, G. Nasti, V. Montesarchio, G. Santabarbara, S. Leo, U. Malapelle, G. Rosati, I. Lolli, E. Tamburini, A. Colombo, D. Santini, L. Silvestro, A. Leone, C. Vitagliano, G. Troncone, A. Sobrero, D. Giannarelli, A. Budillon, A. Avallone
Journal: Annals of Oncology (2023)
P-278 Survival impact and predictive scores for thrombosis associated with pancreatic ductal adenocarcinoma (PDAC)
Authors: A. Romano, J. Gavira, A. Villalba, J. Sanz, M. Molina, F. Bosma, S. Sanchez, J. Tapia, A. Piedra, M. Aguado, F. Pelegrín, B. Martin-Cullell, R. Terés, D. Paez, P. Cerdà
Journal: Annals of Oncology (2023)
P-23 Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study
Authors: T. Kato, D. Kotani, A. Takashima, T. Satoh, T. Masuishi, Y. Komatsu, M. Shiozawa, T. Esaki, N. Izawa, S. Takeuchi, H. Bando, S. Iwasa, H. Hasegawa, T. Yamaguchi, H. Taniguchi, S. Yamada, T. Yoshino
Journal: Annals of Oncology (2023)
P-3 Real-world dosing patterns of regorafenib in patients with metastatic colorectal cancer in Spain: The RE-SEARCH study
Authors: A. López Muñoz, E. González-Flores, R. Afonso, A. Carral Maseda, P. Pimentel, C. López-López, R. Jimeno, R. Fuentes Mateos, J. Reina Zoilo
Journal: Annals of Oncology (2023)
Clinical impact of Xpert® MTB/RIF Ultra for pulmonary TB diagnosis under routine conditions in a reference center in Brazil
Authors: A.P. Santos, D.R. Silva, G. Delazare, J.G. Rodrigues, M.C.F.F. de Aguiar, F.M. Romano, A. Kritski, F.C.Q. Mello
Journal: Pulmonology (2023)
P-219 Non-operative management of localized mismatch repair deficient colon cancer: A real-world perspective
Authors: S. Chakrabarti, J. Selfridge, E. Steinhagen, M. Parish, A. Mohamed, D. Bajor, S. Stein, L. Ocuin, J. Miller-Ocuin, A. Mahipal, A. Shreenivas
Journal: Annals of Oncology (2023)
P-169 Early-onset biliary tract cancer: An overview of clinical presentation, risk factors, molecular profile and outcome in a multicentric Italian cohort
Authors: C. Vivaldi, V. Genovesi, F. Nichetti, V. Zanuso, M. Rimini, L. Antonuzzo, V. Formica, A. Pretta, I. Pecora, F. Salani, E. Gusmaroli, S. Bozzarelli, E. Vasile, C. Pircher, D. Lavacchi, C. Morelli, S. Rota, L. Fornaro, A. Casadei Gardini, L. Rimassa, G. Masi
Journal: Annals of Oncology (2023)
P-58 An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma
Authors: E. Élez, D. Shepard, C. Smolenschi, T. Bekaii-Saab, J. Jac
Journal: Annals of Oncology (2023)
P-73 BXQ-350: A phase 1b/2 placebo-controlled, double-blind study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma
Authors: R. Patel, K. Chung, D. Flora, J. Fuloria, V. Sharma, R. Curry, M. Gazda, J. Purvis, G. Tapolsky, R. Takigiku
Journal: Annals of Oncology (2023)
P-57 Atezolizumab in combination with bevacizumab in patients with unresectable HCC previously untreated with systemic therapy: Interim analysis results from phase IIIb Italian AMETHISTA trial
Authors: E. Martinelli, G. Masi, F. Piscaglia, G. Cabibbo, M. Di Maio, A. Gasbarrini, M. Iavarone, E. Pellegrini, V. Mazzaferro, A. Ballestrero, C. Garufi, F. Bergamo, C. Celsa, D. Marino, F. Tovoli, F. Ponziani, T. Pressiani, C. Astolfi, F. Ciardiello, B. Daniele, L. Rimassa
Journal: Annals of Oncology (2023)
PD-26 Efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal versus gastric cancers: A large, multicenter, cohort study
Authors: G. Mazzoli, F. Nichetti, K. Shitara, R. Cohen, S. Lonardi, E. Elez, M. Fakih, S. Klempner, P. Jayachandran, S. Maron, L. Fornaro, L. Salvatore, Z. Valerie, Y. Aoki, M. Ambrosini, C. Cremolini, G. Randon, M. Overman, T. André, F. Pietrantonio
Journal: Annals of Oncology (2023)
P-111 PD1 and LAG3 inhibition as second+ line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer
Authors: J. Mencel, F. Turkes, L. Barber, B. Challoner, M. Buzzetti, A. Tran, H. Chen, N. McCafferty, A. Woolston, R. Crux, I. Rana, J. Thomas, V. Borja, R. Begum, E. Johnston, N. Fotiadis, M. Terlizzo, S. Rao, I. Chau, D. Cunningham, M. Gerlinger, N. Starling
Journal: Annals of Oncology (2023)
O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study
Authors: E. Smyth, M. Mauer, C. Cella, I. Ben-Aharon, G. Piessen, L. Wyrwicz, G. Al-Haidari, T. Fleitas Kanonnikoff, V. Boige, M. Stahl, U. Martens, R. Obermannová, C. Gomez-Martin, P. Thuss-Patience, V. Arrazubi, A. Avallone, K. Shiu, M. Collienne, A. Giraut, F. Lordick
Journal: Annals of Oncology (2023)
P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study
Authors: T. Yamada, Y. Kito, K. Sakai, K. Nishio, K. Yamazaki, H. Shoji, T. Tsushima, S. Mitani, K. Shiraishi, H. Yasui, H. Hara, K. Shimozaki, T. Esaki, H. Shimokawa, T. Tsuzuki, S. Kajiura, T. Masuishi, E. Baba, K. Yoshimura, H. Kawakami, S. Hironaka, K. Muro
Journal: Annals of Oncology (2023)
PD-28 Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis
Authors: T. André, D. Hong, J. Deeken, A. Italiano, T. Liu, D. Burcoveanu, R. Norenberg, C. Mussi, R. Xu, A. Drilon, L. Shen
Journal: Annals of Oncology (2023)
PD-29 Could molecular profiling be helpful in daily practice in the treatment of anal carcinoma?
Authors: C. Smolenschi, A. Hollebecque, M. Valéry, A. Boileve, V. Boige, A. Bayle, L. Antoun, A. Tarabay, L. Lacroix, T. Pudlarz, I. Sourrouille, L. Benhaim, J. Durand Labrunie, E. Fernandez de Sevilla, M. Gelli, R. Bahleda, M. Ngo-Camus, C. Nicotra, M. Ducreux, D. Vasseur
Journal: Annals of Oncology (2023)
P-66 Retrospective analysis of the use of total neoadjuvant therapy in high-risk locally advanced rectal cancer in a single institution
Authors: C. Torrado, E. Monescillo, F. Tallafigo, P. Macías Rodríguez, R. Pérez Velasco, A. Barroso, J. Rodriguez, M. Valladares-Ayerbes, I. Gallego Jimenez, A. López Ladrón, L. Limon
Journal: Annals of Oncology (2023)
P-28 Locally advanced gastric cancer under FLOT – real-world data on efficacy of patients with dMMR
Authors: L. Gonçalves, M. Pinho, R. Brás, V. Lobo, I. Pinho, T. Barroso, V. Patel, C. Lopes, A. Mansinho, S. Torres, R. Luís, C. Alvim, L. Costa
Journal: Annals of Oncology (2023)